Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Retatrutide Weight Loss: Results, Timeline & What to Expect
guidesHow much weight can you lose on retatrutide? This guide covers Phase 3 and Phase 2 clinical data, a month-by-month timeline, cross-drug comparison to tirzepatide and semaglutide, body composition breakdown, and what individual factors affect your results.
Retatrutide Results: 24% Weight Loss in 48 Weeks (Trial Data)
guidesRetatrutide results from clinical trials show 24.2% weight loss at 48 weeks with the 12mg dose. Detailed breakdown of trial data, timeline of results, body composition changes, and realistic expectations.
Semaglutide Weight Loss: Results, Timeline & What to Expect
guidesHow much weight can you lose on semaglutide? STEP 1 trial data shows 14.9% mean body weight loss at 68 weeks, with 86.4% of participants losing at least 5%. This guide breaks down the clinical evidence, month-by-month timeline, real-world results, and what factors determine your outcome.